AMGN · Amgen Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.62B | - | $9.56B | $9.18B | $8.15B | - | $8.50B | $8.39B | $7.45B | - |
| Cost of Revenue | $2.74B | - | $3.08B | $3.01B | $2.97B | - | $3.31B | $3.24B | $3.20B | - |
| Gross Profit | $5.87B | - | $6.47B | $6.17B | $5.18B | - | $5.19B | $5.15B | $4.25B | - |
| R&D | $1.72B | - | $1.90B | $1.74B | $1.49B | - | $1.45B | $1.45B | $1.34B | - |
| SG&A | $1.60B | - | $1.72B | $1.69B | $1.69B | - | $1.63B | $1.78B | $1.81B | - |
| Total Operating Expenses | $5.95B | - | $7.03B | $6.52B | $6.97B | - | $6.46B | $6.48B | $6.46B | - |
| D&A | $1.12B | - | $198.00M | $202.00M | $1.39B | - | - | - | $1.40B | - |
| Operating Income | $2.67B | - | $2.53B | $2.66B | $1.18B | - | $2.05B | $1.91B | $991.00M | - |
| Interest Expense | $657.00M | - | $685.00M | $694.00M | $723.00M | - | $776.00M | $808.00M | $824.00M | - |
| Income Tax | $265.00M | - | $705.00M | $136.00M | $243.00M | - | $271.00M | $48.00M | $45.00M | - |
| Net Income | $1.82B | - | $3.22B | $1.43B | $1.73B | - | $2.83B | $746.00M | ($113.00M) | - |
| EPS - Basic | $3.37 | - | $5.98 | $2.66 | $3.22 | - | $5.27 | $1.39 | ($0.21) | - |
| EPS - Diluted | $3.34 | - | $5.93 | $2.65 | $3.20 | - | $5.22 | $1.38 | ($0.21) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.04B | $9.13B | $9.45B | $8.03B | $8.81B | $11.97B | $9.01B | $9.30B | $9.71B | $10.94B |
| Accounts Receivable | $9.14B | $9.57B | $8.49B | $8.70B | $8.13B | $6.78B | $7.32B | $6.93B | $6.78B | $7.27B |
| Inventory | $6.19B | $6.22B | $6.35B | $6.58B | $6.73B | $7.00B | $7.36B | $8.00B | $8.72B | $9.52B |
| Accounts Payable | $2.94B | $2.37B | $2.84B | $3.01B | $2.41B | $1.91B | $2.15B | $2.27B | $1.63B | $1.59B |
| Current Assets | $31.48B | $29.06B | $27.89B | $26.73B | $26.93B | $29.03B | $26.77B | $27.21B | $28.03B | $30.33B |
| Total Assets | $92.50B | $90.59B | $90.14B | $87.90B | $89.37B | $91.84B | $90.88B | $90.91B | $92.98B | $97.15B |
| Current Liabilities | $24.95B | $25.49B | $21.79B | $20.48B | $23.01B | $23.10B | $20.31B | $21.52B | $19.71B | $18.39B |
| Long-term Debt | $51.89B | $50.01B | $52.43B | $53.76B | $54.01B | $56.55B | $56.85B | $57.12B | $60.06B | $63.17B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $9.19B | $8.66B | $9.62B | $7.43B | $6.21B | $5.88B | $7.53B | $5.92B | $5.02B | $6.23B |
| Retained Earnings | ($24.65B) | ($25.11B) | ($23.80B) | ($25.71B) | ($27.14B) | ($27.59B) | ($25.53B) | ($27.12B) | ($27.87B) | ($26.55B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.19B | - | - | - | $1.39B | - | - | - | $689.00M | - |
| Investing Cash Flow | ($716.00M) | - | - | - | ($447.00M) | - | - | - | ($217.00M) | - |
| Financing Cash Flow | $1.44B | - | - | - | ($4.11B) | - | - | - | ($1.71B) | - |
| CapEx | $712.00M | - | - | - | $411.00M | - | - | - | $230.00M | - |
| Free Cash Flow | $1.48B | - | - | - | $980.00M | - | - | - | $459.00M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 68.2% | - | 67.8% | 67.2% | 63.6% | - | 61.1% | 61.4% | 57.0% | - |
| Operating margin | 30.9% | - | 26.4% | 28.9% | 14.5% | - | 24.1% | 22.8% | 13.3% | - |
| EBITDA margin | 43.9% | - | 28.5% | 31.1% | 31.5% | - | - | - | 32.1% | - |
| Net margin | 21.1% | - | 33.7% | 15.6% | 21.2% | - | 33.3% | 8.9% | -1.5% | - |
| Free cash flow margin | 17.1% | - | - | - | 12.0% | - | - | - | 6.2% | - |
| FCF / Net income | 0.81 | - | - | - | 0.57 | - | - | - | -4.06 | - |
| R&D / Revenue | 19.9% | - | 19.9% | 19.0% | 18.2% | - | 17.1% | 17.3% | 18.0% | - |
| SG&A / Revenue | 18.6% | - | 18.0% | 18.4% | 20.7% | - | 19.1% | 21.3% | 24.3% | - |
| Effective tax rate | 12.7% | - | 18.0% | 8.7% | 12.3% | - | 8.7% | 6.0% | - | - |
| Return on assets | 2.0% | - | 3.6% | 1.6% | 1.9% | - | 3.1% | 0.8% | -0.1% | - |
| Return on equity | 19.8% | - | 33.4% | 19.3% | 27.9% | - | 37.6% | 12.6% | -2.3% | - |
| Return on invested capital | 3.8% | - | 3.3% | 4.0% | 1.7% | - | 2.9% | 2.8% | 1.2% | - |
| Liquidity | ||||||||||
| Current ratio | 1.26 | 1.14 | 1.28 | 1.31 | 1.17 | 1.26 | 1.32 | 1.26 | 1.42 | 1.65 |
| Quick ratio | 1.01 | 0.90 | 0.99 | 0.98 | 0.88 | 0.95 | 0.96 | 0.89 | 0.98 | 1.13 |
| Cash ratio | 0.48 | 0.36 | 0.43 | 0.39 | 0.38 | 0.52 | 0.44 | 0.43 | 0.49 | 0.60 |
| Leverage | ||||||||||
| Debt / Equity | 5.65 | 5.78 | 5.45 | 7.24 | 8.70 | 9.62 | 7.55 | 9.64 | 11.96 | 10.14 |
| Debt / Assets | 0.56 | 0.55 | 0.58 | 0.61 | 0.60 | 0.62 | 0.63 | 0.63 | 0.65 | 0.65 |
| Debt / EBITDA | 13.72 | - | 19.25 | 18.81 | 21.06 | - | - | - | 25.13 | - |
| Interest coverage | 4.1x | - | 3.7x | 3.8x | 1.6x | - | 2.6x | 2.4x | 1.2x | - |
| Equity multiplier | 10.07 | 10.46 | 9.37 | 11.83 | 14.40 | 15.63 | 12.07 | 15.34 | 18.51 | 15.59 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | - | 0.11 | 0.10 | 0.09 | - | 0.09 | 0.09 | 0.08 | - |
| Inventory turnover | 0.44 | - | 0.49 | 0.46 | 0.44 | - | 0.45 | 0.40 | 0.37 | - |
| Days sales outstanding | 387d | - | 324d | 346d | 364d | - | 314d | 302d | 332d | - |
| Days inventory outstanding | 823d | - | 752d | 798d | 828d | - | 812d | 902d | 995d | - |
| Days payable outstanding | 390d | - | 336d | 365d | 296d | - | 237d | 256d | 186d | - |
| Cash conversion cycle | 819d | - | 740d | 779d | 896d | - | 889d | 948d | 1141d | - |
| Valuation | ||||||||||
| P / E | 105.3x | - | 47.6x | 105.4x | 97.4x | - | 61.7x | 226.4x | - | - |
| P / B | 20.8x | - | 15.9x | 20.3x | 27.2x | - | 23.2x | 28.5x | 30.3x | - |
| P / S | 22.2x | - | 16.0x | 16.5x | 20.7x | - | 20.5x | 20.2x | 20.5x | - |
| EV / EBITDA | 61.1x | - | 71.9x | 68.9x | 83.3x | - | - | - | 84.8x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 5.8% | - | 12.4% | 9.4% | 9.4% | - | 23.2% | 20.1% | 22.0% | - |
| Revenue CAGR (3y) | 12.2% | - | 12.8% | 11.7% | 9.3% | - | 8.2% | 8.7% | 8.1% | - |
| Revenue CAGR (5y) | 7.9% | - | 8.3% | 8.1% | 5.8% | - | 8.2% | 7.4% | 6.0% | - |
| Gross profit growth (YoY) | 13.4% | - | 24.7% | 19.7% | 22.0% | - | 1.9% | -0.4% | -3.1% | - |
| Operating income growth (YoY) | 126.3% | - | 23.4% | 39.1% | 18.9% | - | 1.3% | -28.9% | -48.4% | - |
| Net income growth (YoY) | 5.1% | - | 13.6% | 92.0% | - | - | 63.6% | -45.9% | - | - |
| EPS growth (YoY) | 4.4% | - | 13.6% | 92.0% | - | - | 62.1% | -46.3% | - | - |
| EPS CAGR (3y) | -14.2% | - | 14.2% | 2.7% | 6.1% | - | 16.4% | 19.4% | - | - |
| EPS CAGR (5y) | 3.4% | - | 11.6% | -2.8% | 0.8% | - | 9.8% | -17.3% | - | - |
| FCF growth (YoY) | 50.7% | - | - | - | 113.5% | - | - | - | -36.3% | - |
| FCF CAGR (5y) | -5.3% | - | - | - | -13.2% | - | - | - | -23.3% | - |
| Book value growth (YoY) | 48.1% | 47.3% | 27.8% | 25.4% | 23.6% | -5.7% | -1.7% | -12.6% | -6.1% | 70.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$62.67B totalProduct$35.15B · 56.1%
Other Products$5.44B · 8.7%
Prolia$2.98B · 4.8%
Enbrel$2.20B · 3.5%
Otezla$1.84B · 2.9%
TEPEZZA$1.76B · 2.8%
Repatha$1.66B · 2.7%
Product And Service Other$1.60B · 2.6%
EVENITY$1.60B · 2.6%
TEZSPIRE$1.48B · 2.4%
Xgeva$1.35B · 2.2%
KRYSTEXXA$1.34B · 2.1%
BLINCYTO$1.05B · 1.7%
Nplate$1.03B · 1.6%
KYPROLIS$913.00M · 1.5%
Vectibix$604.00M · 1.0%
Aranesp$416.00M · 0.7%
Be One$266.00M · 0.4%
Geographic
$36.75B totalUS$26.42B · 71.9%
Non Us$10.33B · 28.1%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing AMGEN INC against the 5 most active filers in the same SIC group.
Dividends
$9.80/share trailing 12 months · +5.8% YoY
| Ex-date | Per share |
|---|---|
| May 15, 2026 | $2.5200 |
| Feb 13, 2026 | $2.5200 |
| Nov 21, 2025 | $2.3800 |
| Aug 22, 2025 | $2.3800 |
| May 16, 2025 | $2.3800 |
| Feb 14, 2025 | $2.3800 |
| Nov 18, 2024 | $2.2500 |
| Aug 16, 2024 | $2.2500 |
| May 16, 2024 | $2.2500 |
| Feb 15, 2024 | $2.2500 |
| Nov 16, 2023 | $2.1300 |
| Aug 17, 2023 | $2.1300 |
| May 17, 2023 | $2.1300 |
| Feb 14, 2023 | $2.1300 |
| Nov 16, 2022 | $1.9400 |
| Aug 17, 2022 | $1.9400 |
| May 16, 2022 | $1.9400 |
| Feb 14, 2022 | $1.9400 |
| Nov 15, 2021 | $1.7600 |
| Aug 16, 2021 | $1.7600 |
| May 14, 2021 | $1.7600 |
| Feb 11, 2021 | $1.7600 |
| Nov 13, 2020 | $1.6000 |
| Aug 14, 2020 | $1.6000 |